DCT and melanoma: The TRP-2 peptide is implicated in the immunotherapy of human and murine melanoma, as it is recognized by both human and murine cytotoxic T-cells and is presented by the MHC class I haplotypes HLA-A*0201 and H2-Kb, respectively, leading to the effective induction of antitumor immunity.